Malú Tansey, PhD Linkedin Twitter Malú Gámez Tansey, Ph.D. is a Professor of Neurology and the James A. Caplin MD, Chair in Alzheimer’s Disease at Indiana University School of Medicine and Director of Neuroimmunology Research Group & Executive Associate Director of Education at the Stark Neuroscience Research Institute. Her lab focuses on the role of inflammation […]
Joseph Helpern, PhD Joseph, A. Helpern, Ph.D. is the founder of the Charleston Conference on Alzheimer’s Disease. He has been involved with the development of magnetic resonance imaging (MRI) since the inception of the field focusing mainly in the area of neurodegenerative disorders. His most current research involves the development of diffusional kurtosis imaging, a
Karen E. Duff, PhD Twitter Prof Karen Duff is a leader in the field of neurodegenerative disease having first started her career as a PhD student in the Cambridge department of Nobel Prize winner Sydney Brenner. Prof Duff has worked for over 30 years on Alzheimer’s disease and the tauopathies, for which she was awarded
Peter Davies, PhD We are deeply saddened by the loss of a great friend and one of Alzheimer’s brilliant scientific minds. Peter Davies will be forever remembered by the CCAD family. It is not the most distinguished achievements that men’s virtues or vices may be best discovered; but very often an action of small note.
Ralph Nixon, MD, PhD Dr. Ralph Nixon currently serves as Vice Chairman on the Medical and Scientific Advisory Board of the national Alzheimer’s Association and on the Governor’s Commission on Alzheimer’s Disease for the State of New York. Dr. Nixon’s work is the first to call attention to the importance of proteases in Alzheimer’s disease.
Alison Goate, DPhil Dr. Goate is a renowned neuropsychiatric researcher and molecular geneticist whose pioneering work falls within two areas: gene discovery and modeling disease mutations. She is best known for identifying the first gene mutation linked to an inherited form of Alzheimer’s disease, and for finding common and rare variants that influence the risk
Charles Dorego, PhD Charles “Charlie” Dorego is the Senior Vice President and General Counsel of Glenwood Management Corp., one of the largest and most preeminent real estate development companies in New York City. Charlie brings nearly 30 years of diverse, hands-on experience in all aspects of the Real Estate industry. He joined Glenwood Management in
Federica del Monte, MD, PhD Federica del Monte is a clinician-scientist, Associate Professor in Medicine in the Department of Medicine, Division of Cardiology at the Medical University of South Carolina, Director of the Christie’s Heart & Brain Program. This will represent the first program to study the mechanisms linking those two diseases either as a systemic
Federica del Monte Read More »
Hui Zheng, PhD Dr. Zheng is a leading authority on amyloid precursor protein (APP) and the presenilins, two proteins involved in the APP processing pathway that produces the Alzheimer’s-linked fragment beta-amyloid. Working with molecular and cellular techniques and genetically engineered mice, she has conducted field-leading explorations of the mechanisms through which rare genetic changes in
George Bartzokis, MD, PhD Dr. George Bartzokis was born in a Greek refugee camp in Romania and at the age of fourteen, he immigrated along with his family to Boston, MA. Once there, he taught himself English, worked his way through school, and eventually graduated from Harvard College. He then went on to earn his
